McGill research shows positive results for CVT-E002 in a cancer model

A preclinical study conducted by McGill researcher Dr. Sandra Miller has shown that a proprietary extract of ginseng CVT-E002 may have potential as a cancer therapy and immune system booster during cancer treatment.

Dr. Miller, a professor in the Department of Anatomy and Cell Biology in the Faculty of Medicine, launched the study in November 2004. She said that although further experiments are needed to support advancement into clinical development and research involving humans, "we've shown that it enhances the absolute numbers of the natural killer (NK) cells and monocytes that are the first line of defence against tumours in tumour-bearing mice."

The data also indicate that CVT-E002 was associated with a statistically significant increase in survival rates versus the placebo group. There were no observable adverse effects associated with CVT-E002 treatment.

Dr. Miller will be presenting these findings at an international scientific conference in the near future.

The study was conducted on behalf of Edmonton-based CV Technologies Inc., makers of CVT-E002, and funded by the National Research Council under the Industrial Research Assistance Program (IRAP).